{"id":1581,"date":"2026-01-27T18:36:46","date_gmt":"2026-01-27T17:36:46","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/engot-ov83-catalina-2\/"},"modified":"2026-01-28T15:13:04","modified_gmt":"2026-01-28T14:13:04","slug":"engot-ov83-catalina-2","status":"publish","type":"post","link":"https:\/\/studienportal-eierstockkrebs.de\/en\/engot-ov83-catalina-2\/","title":{"rendered":"ENGOT-ov83 \/ CATALINA-2"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

ENGOT-ov83 \/ CATALINA-2<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Therapeutic study to evaluate the efficacy and safety of the new compound TORL-1-23 in patients with advanced, platinum-resistant ovarian cancer<\/strong><\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

CATALINA-2 is an international phase 2 trial investigating a new, targeted drug called TORL-1-23<\/em> in women with advanced, platinum-resistant ovarian cancer <\/strong>(ovary, fallopian tube or peritoneum). This refers to patients in whom the disease has recurred after platinum-based chemotherapy or whose tumor no longer responds to it. The drug targets a specific protein on the surface of tumor cells called claudin-6 (CLDN6)<\/strong>. The aim of the study is to test how well TORL-1-23<\/em> works and how well it is tolerated. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

What is being investigated in this study? <\/strong><\/p>

Ovarian cancer is often difficult to treat, especially if it recurs after chemotherapy with platinum-based drugs (e.g. carboplatin) or has become insensitive to this treatment. Such cases are referred to as platinum-resistant ovarian cancer. <\/p>

Researchers have discovered that a specific protein – claudin-6 (CLDN6) – is present in large quantities in many of these tumors. This protein is normally only present in very early stages of cell development and is rarely found in healthy tissue. CLDN6 is therefore considered a promising target for specifically attacking tumor cells without severely damaging healthy tissue. <\/p>

TORL-1-23<\/em> is a so-called antibody-drug conjugate (ADC). This means that this drug consists of an antibody that specifically recognizes and binds CLDN6 proteins on the tumour cell. An active substance is coupled to the antibody, which is introduced into the tumor cell and can destroy the cancer cell there. <\/p>

An earlier phase 1 trial has already shown that TORL-1-23 was well tolerated and can be active against tumors with CLDN6 expression. The CATALINA-2 trial is now investigating how effective and safe the drug is in a larger group of patients. <\/p>

What is the aim of the study? <\/strong><\/p>

The main aim of the study is to find out how well TORL-1-23<\/em> as the sole therapy (monotherapy) delays the progression of the disease and how long patients benefit from the treatment.
In addition, the study will investigate which dosage works best and is also well tolerated.<\/p>

What is the survey procedure?<\/strong><\/p>

The CATALINA-2 study consists of two sections:<\/strong><\/p>